HomeProductsBioactive CompoundsMAPK/ERK Pathwayp38 MAPKPexmetinib
Chemical structure of CAS 945614-12-0

Pexmetinib

CAS No.945614-12-0
MDL No.MFCD28502055
MFC31H33FN6O3
MW556.60
InChI KeyLNMRSSIMGCDUTP-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.945614-12-0
Product NamePexmetinib

Biological Targets

MAPK14·TEK

Associated Conditions

myelodysplastic syndrome
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Cancer research • Vol. 76, Issue 16 • 2016
PMID: 27287719PMC: PMC5398415DOI: 10.1158/0008-5472.CAN-15-3062

A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 21, Issue 5 • 2015
PMID: 25480830PMC: PMC4348327DOI: 10.1158/1078-0432.CCR-14-1765

p38 MAPK in MDS.

Aging • Vol. 7, Issue 6 • 2015
PMID: 26081220PMC: PMC4505155DOI: 10.18632/aging.100757

Signal transduction inhibitors in treatment of myelodysplastic syndromes.

Journal of hematology & oncology • Vol. 6 • 2013
PMID: 23841999PMC: PMC3716523DOI: 10.1186/1756-8722-6-50

Documentation